🔥 PHENIX trial: SLN alone = noninferior DFS + fewer complications (lymphedema 5.2% vs. 19.1%) in early-stage CC. 💯 Will this finally change clinical practice? I’m all for de-escalation! @IJGConline @ESGO_society @ENYGO_official https://t.co/7HkPlJIaDh

🔥 PHENIX trial: SLN alone = noninferior DFS + fewer complications (lymphedema 5.2% vs. 19.1%) in early-stage CC. 💯 Will this finally change clinical practice? I’m all for de-escalation! @IJGConline @ESGO_society @ENYGO_official https://t.co/7HkPlJIaDh

#ESMO25 @myESMO Another session - another impressive report out on ADCs. Here- Raludotatug deruxtecan in platinum resistant ovarian cancer. (I am involved so am declaring COI) BUT - best dose optimization so far for an ADC in gyn, randomized, biomarkers evaluated on fresh bx,

The challenging setting of platinum-resistant ovarian cancer received attention at #ESMO2025. KEYNOTE-B96/ENGOT-ov65 results presented at the Presidential Session. The iconic Prof. Nicoletta Colombo on the stage, and always next to #gynonc patients! @myESMO @IEOufficiale

📢 Huge day at #ESMO25! The Presidential Session delivered multiple clinical practice-changing studies that will redefine standards of care across oncology. 🔬👏 Grateful to witness innovation turning into impact. @myESMO

#myESMO KEYNOTE B96 Improved PFS HR 0.70 in ITT, OS improved in ITT per press release. Only 1-2 priors, only 46% with prior bev, very low prior PARPi. How do we compare to MIRV and nab-pac/relacorilant? And with the tsunami of ADCs - does this change "the" SOC? Not sure

Honored to have chaired my first session at @myESMO 2025 today, focusing on post-PARP inhibitor era in #ovariancancer. An inspiring discussion with brilliant speakers and colleagues, exploring new strategies to both overcome and bypass PARPi resistance. @IEOufficiale

Honored to have chaired my first session at @myESMO 2025 today, focusing on post-PARP inhibitor era in #ovariancancer. An inspiring discussion with brilliant speakers and colleagues, exploring new strategies to both overcome and bypass PARPi resistance. @IEOufficiale

PhD in Network Oncology and Precision Medicine 🧬💊👨🏻‍🏫 Department of Experimental Medicine @SapienzaRoma Waiting for PhD thesis defense… 🔜

Il 10 e l’11/10 si è svolto il congresso “La nuova era nella gestione del Carcinoma Endometriale: dalle Linee Guida ai Percorsi Diagnostici e Terapeutici Applicabili”, un evento dedicato alle ultime novità nella cura del tumore dell’endometrio. Grazie a tutti💙

Two amazing days at the @IEOufficiale in Milan, with dear friends and colleagues, discussing the new era in endometrial cancer management. The future is bright for our patients! 💫 #ieo #EndometrialCancer #gynonc

I am truly honored to serve as Chair of the very first gynonc session at @myESMO 2025 in Berlin. Together with an outstanding panel of experts, we will be discussing a highly relevant and evolving topic: ➡️ Treatment strategies for pts with OC post-PARPi. 🔜 Can’t wait! #ESMO2025

Dopo la pausa estiva riparte il “Progetto BAU”: cani appositamente addestrati offrono supporto emotivo a pazienti e accompagnatori, regalando momenti di serenità e conforto. Scopri le prossime date 👉 https://t.co/UCsytv4w9Y

Proud to be, together with my dear friend @BoganiGiorgio, co-first author of this paper on uLMS, reflecting an international multidisciplinary statement on uLMS including a lot of KOLs worldwide. Cannot miss this 🔥 @IJGConline @IGCSociety @ESGO_society @ENYGO_official

#EditorsChoice #UterineLeiomyosarcoma is rare, aggressive, and hard to diagnose. Multidisciplinary care is key. 👉 Learn more in the latest review: https://t.co/wqCZpYfRKf @gcarusomd @BoganiGiorgio @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society

Thrilled to be in Florence to share insights on mirvetuximab soravtansine for ovarian cancer. Looking forward to a great event! #OvarianCancer #ADC #mirvetuximab @abbvie

Per il sesto anno consecutivo, lo IEO si conferma 1° in Italia e fra i migliori ospedali al mondo nella classifica “World’s Best Specialized Hospitals 2026”, stilata dal settimanale internazionale Newsweek e la società di ricerca Statista. 👉 https://t.co/wsMzImVJvi

Check our 📄 assessing surrogacy between #PFS and #OS in advanced/metastatic #endometrialcancer @IJGConline @EORTC ⚪Context dependent association, particularly in Chemo+IO ⚪Impact of Rt? @ramon_yarza @gcarusomd @ArantzazuBarqu1 @fg_herrera Free access 👇 https://t.co/9ePW92Vfu1

It’s been a month since the publication of our @JAMA_current review on ovarian cancer — an incredibly well-structured, insightful, and highly educational piece. If you missed it, you can find the full article here: https://t.co/sRFPPCVNXr

It is great to see so many enthusiastic people working together and we are proud of everyone of you from ESGO and ENYGO 👏👏👏 Thanks to all for their contribution and we are looking forward to our future projects. #esgosociety #friends #gynaecology #oncology